The earnings before interest, tax, depreciation and ammortisation (EBITDA) margins expanded 210 basis points YoY to 31.3 percent; however, on sequential basis (QoQ), Laurus#39; EBITDA margins were down by 250 basis points.Laurus Labs Q1FY22 net profit surges 40% to Rs 241 crore, led by anti-HIV formulation sales
The earnings before interest, tax, depreciation and ammortisation (EBITDA) margins expanded 210 basis points YoY to 31.3 percent; however, on sequential basis (QoQ), Laurus#39; EBITDA margins were down by 250 basis points.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
The company#39;s vaccine candidate -Covaxin- has been developed in collaboration with the Indian Council of Medical Research (ICMR) - Natio...
No comments:
Post a Comment